Biocept, Inc. Announces New Methods for Isolating Previously Unrecognized Circulating Tumor Cells (CTCs) San Diego, California – Biocept, Inc., a privately?held, CLIA certified laboratory testing company focused on detection and analysis of circulating tumor cells in cancer patients, announced
Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs) San Diego, CA ? Biocept, Inc. today reported that its scientists and academic collaborators will present three posters at the 34th annual San Antonio Breast Cancer
Biocept Announces Allowance of Key Patent for its Circulating Tumor Cell Platform San Diego, California: ? Biocept, Inc., a privately?held CLIA?certified laboratory testing company, focused on the detection and analysis of circulating tumor cells (CTCs) in blood samples from cancer patients,
Biocept Publishes on Mechanics and Performance of its Onco CEE™ Platform for Circulating Tumor Cells (CTCs) in Cancer Patients San Diego, California: – Biocept, Inc., a privately-held CLIA-certified laboratory testing company, focused on the detection and analysis of circulating tumor cells (CTCs)
Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 status in Breast Cancer Patients San Diego, California: ? Biocept, Inc., a privately-held CLIA-certified laboratory testing company, focused on the detection and analysis of circulating tumor cells (CTCs)
Biocept, Inc. announces availability of its new breast cancer test, OncoCEE-BR™ utilizing circulating tumor cells (CTCs) Capture, detection and enumeration Determination of HER2/neu status Biocept, Inc., an advanced diagnostic CLIA-certified service laboratory developing novel tests for the
Biocept, Inc. announces new CFO Biocept, Inc. announced today that it has appointed William G. Kachioff as Senior Vice President, Finance and Chief Financial Officer. As CFO, Mr. Kachioff will be responsible for management of the company’s accounting, finance, treasury, investor relations, risk
Biocept and Academic Collaborators to Present Poster at ASCO on Circulating Tumor Cells (CTCs) Biocept, Inc. today reported that its scientists and academic collaborators will present a poster at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago,
Lyle Arnold, PhD and Michael Dunn Join Biocept Management Team SAN DIEGO / — Biocept, Inc. announced today that Lyle Arnold, PhD and Michael Dunn, MBA have joined Biocept’s Management Team. Dr. Arnold will serve as Senior Vice President and Chief Scientific Officer (CSO) and Mr.
